News stories about Acasti Pharma (NASDAQ:ACST) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acasti Pharma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.0091899549729 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
Acasti Pharma (NASDAQ ACST) opened at $3.10 on Tuesday. Acasti Pharma has a 52-week low of $1.11 and a 52-week high of $3.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.55 and a current ratio of 4.55.
Separately, ValuEngine raised shares of Acasti Pharma from a “sell” rating to a “hold” rating in a report on Monday.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/21/acasti-pharma-acst-earning-somewhat-favorable-press-coverage-accern-reports.html.
Acasti Pharma Company Profile
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.